27.01.2025
CPNN+ P.I awarded ARIA funding for future adoption of neurotechnologies
Funding from the Advanced Research + Invention Agency (ARIA) to advance research that could unlock next-generation precision neurotechnologies.
Prof. Ben Seymour has been awarded funding to allow researchers from Oxford, as well as Warwick Business School, to develop a new tool for predicting patient preferences and possible uptake of interventional neurotechnologies. Ben says:
‘We’re really excited about this opportunity to think clearly and openly about the really transformational interventions that we can design and be part in some way of the next generation of treatments of neurological and mental health challenges. We’re an interdisciplinary team spanning clinical neuroscience, behavioural and health economics, computational psychology, and game theory. We work together as part of the Oxford Health Biomedical Research Centre, and have come together with Warwick Business School to create this unique team that spans cutting-edge science and health policy’. For more information, please visit https://www.aria.org.uk/opportunity-spaces/scalable-neural-interfaces/precision-neurotechnologies/
More news
See all
‘What We Carry’ exhibited at The Corridor Gallery
Our recent chronic pain PPI project, 'What We Carry: Living with Pain' is currently on exhibition at the John Radcliffe Hospital, Oxford, within The Corridor Gallery until 6th December 2025.
PPI Project – ‘What We Carry: Living with Pain’
Amplifying Voices in Pain Research. This powerful project explores chronic pain through photography, writing, and storytelling. The work – created in collaboration with pain sufferers – gives voice to experiences often invisible and misunderstood, offering both a creative outlet and vital insight for researchers and clinicians.
New Oxford-led project aims to revolutionise chronic pain treatment
The University of Oxford is to lead a new six-year, £11 million project backed by the Engineering and Physical Sciences Research Council (EPSRC) which aims develop a new generation of personalised treatments capable of reducing or abolishing chronic pain.